Terazosin Hydrochloride — Active Pharmaceutical Ingredient

Terazosin Hydrochloride is an active pharmaceutical ingredient found in 3 FDA-approved drug products. Forms: TABLET, CAPSULE, SOLUTION. Routes: ORAL.

This content is for informational purposes only. Always consult a healthcare professional.

Terazosin Hydrochloride (3 brand names, 3 dosage forms, 1 route)

Available dosage forms: TABLET, CAPSULE, SOLUTION.

Routes of administration: ORAL.

Brand Names

  • HYTRIN
  • TERAZOSIN HYDROCHLORIDE
  • TEZRULY

Indications and Usage

Terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin capsules. The long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin capsules are also indicated for the treatment of hypertension. Terazosin capsules can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.

Dosage and Administration

If terazosin capsules administration is discontinued for several days, therapy should be reinstituted using the initial dosing regimen.

Contraindications

Terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.

Drug Interactions

In controlled trials, terazosin have been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine, ibuprofen, indomethacin); antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole); anticholinergic/sympathomimetics (e.g., phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); antigout (e.g., allopurinol); antihistamines (e.g., chlorpheniramine); cardiovascular agents (e.g., atenolol, hydrochlorothiazide, methyclothiazide, propranolol); corticosteroids; gastrointestinal agents (e.g., antacids); hypoglycemics; sedatives and tranquilizers (e.g., diazepam).

Overdosage

Should overdosage of terazosin capsules lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, shock should first be treated with volume expanders. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that terazosin is 90-94% protein bound; therefore, dialysis may not be of benefit.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.